GAITHERSBURG, Md., Feb. 20,
2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a
global company advancing protein-based vaccines with its
Matrix-M™ adjuvant, today announced it will report its fourth
quarter and full year 2023 financial results and operational
highlights at 8:30 a.m. Eastern Standard
Time (EST) on Wednesday, February 28,
2024. Details of the event and replay are as follows:
Conference call
details:
|
|
Date:
|
February 28,
2024
|
Time:
|
8:30 a.m. U.S.
EST
|
URL to register
phone:
|
https://emportal.ink/3SqJSJv
|
Dial-in
number:
|
(888) 664-6383
(Domestic) or
|
|
(+1) (617) 892-4906
(International)
|
Webcast:
|
ir.novavax.com/events
|
- Participants can join the conference call without operator
assistance by registering and entering their phone number with the
above URL to receive an instant automated call back.
- Participants can also dial direct to be entered into the
call by an Operator and will be prompted to request to join the
Novavax, Inc. call.
- To ensure a timely connection, it is recommended that
participants join at least 10 minutes prior to the scheduled
webcast.
Replay
details:
|
|
Date:
|
Available starting at
11:30 a.m. EST, February 28, 2024, until 11:59 p.m. U.S. EST, March
6, 2024
|
Dial-in
number:
|
(416) 764-8677
(Domestic) or
|
|
(+1) (888) 390-0541
(International)
|
Passcode:
|
789473#
|
Webcast:
|
ir.novavax.com/events,
until May 28, 2024
|
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes
improved health by discovering, developing and commercializing
innovative vaccines to help protect against serious infectious
diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a
differentiated vaccine platform that combines a recombinant protein
approach, innovative nanoparticle technology and Novavax's patented
Matrix-M adjuvant to enhance the immune response. The Company's
portfolio includes its COVID-19 vaccine and its pipeline includes a
vaccine for COVID-19 and influenza combined. In addition, Novavax's
adjuvant is included in the University of
Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please
visit novavax.com and LinkedIn for more information.
View original
content:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2023-financial-results-and-operational-highlights-on-february-28-2024-302065938.html
SOURCE Novavax, Inc.